The Journey of Semaglutide

Oral semaglutide (Rybelsus) is co-formulated with the absorption
enhancer sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC), which transiently raises local
gastric pH around the tablet, reducing proteolytic degradation and facilitating transcellular
absorption across the gastric mucosa — an unprecedented absorption mechanism for a peptide
drug. Oral bioavailability is approximately 1% but sufficient for once-daily dosing with
fasting required (no food or drink except water for 30 minutes after). Subcutaneous semaglutide
(Ozempic, Wegovy) achieves ~89% bioavailability after injection, with peak plasma concentrations
at 1-3 days. The subcutaneous absorption is slow and sustained due to depot formation at the
injection site and the large molecular weight (~4114 Da). Subcutaneous administration in the
abdomen, thigh, or upper arm gives similar absorption profiles.

Semaglutide's molecular engineering is designed around
maximizing albumin binding. A C18 fatty diacid is attached via a linker to lysine-34 of the
GLP-1 backbone, enabling strong non-covalent binding to human serum albumin. This binding
dramatically reduces renal filtration (semaglutide's Vd is approximately 12.5 L, barely
exceeding plasma volume), slows receptor internalization kinetics, and protects against
proteolytic degradation. At steady state, over 99% of circulating semaglutide is albumin-
bound. The drug crosses the blood-brain barrier to a limited extent via transcytosis mediated
by albumin receptors (FcRn, megalin), reaching hypothalamic GLP-1 receptors that drive
appetite suppression — a critical mechanism for the substantial weight loss observed with
therapeutic doses.

Semaglutide activates the glucagon-like peptide-1 receptor
(GLP-1R), a class B G protein-coupled receptor expressed in pancreatic beta cells, alpha cells,
gastric mucosa, intestinal L-cells, vagal afferents, hypothalamus, brainstem, heart, and kidney.
In pancreatic beta cells, GLP-1R coupling to Gs activates adenylyl cyclase, raising intracellular
cAMP, activating PKA and EPAC2 (exchange protein activated by cAMP), and potentiating glucose-
stimulated insulin secretion — without directly causing insulin release in the fasting state.
In alpha cells, GLP-1R activation suppresses glucagon secretion. Delayed gastric emptying
reduces post-prandial glucose excursions by slowing nutrient delivery to the intestine. Central
GLP-1R activation in the arcuate nucleus and nucleus of the solitary tract reduces food intake,
increases satiety signaling, and lowers body weight — the basis for semaglutide's approval in
obesity management.

Semaglutide's backbone contains an Aib (alpha-aminoisobutyric acid)
substitution at position 8, replacing alanine to prevent cleavage by DPP-4. Additionally,
arginine at position 34 is substituted with lysine (site of fatty acid attachment), and lysine
at position 26 is substituted with arginine. These modifications together create a molecule
resistant to both DPP-4 (the main incretin degrading enzyme) and neutral endopeptidase. The
primary metabolic route is sequential cleavage of the peptide backbone by ubiquitous endopeptidases
and exopeptidases, followed by fatty acid beta-oxidation. Metabolites are pharmacologically
inactive. No specific CYP450 enzymes are involved — a major clinical advantage avoiding
conventional drug-drug interactions.

Semaglutide metabolites are excreted in urine and feces in
approximately equal proportions. The elimination half-life of approximately 7 days (168 hours)
is the longest of any GLP-1 receptor agonist, enabling once-weekly subcutaneous dosing. This
prolonged half-life means that steady-state concentrations require 4-5 weeks to achieve with
weekly dosing. Renal impairment does not significantly alter semaglutide pharmacokinetics,
as the drug is not excreted intact by the kidney (high albumin binding prevents filtration).
No dose adjustment is required in renal or hepatic impairment. After discontinuation, semaglutide
activity persists for approximately 5 weeks.

Semaglutide at 0.5-1 mg weekly reduces HbA1c by 1.5-1.8% in type 2
diabetes; at 2.4 mg weekly (Wegovy dose), achieves an average 14-17% body weight reduction.
The SUSTAIN-6 and SELECT trials demonstrated cardiovascular risk reduction in high-risk patients.
GI side effects (nausea, vomiting, diarrhea) are the primary limitation, dose-dependent, and
tend to attenuate with gradual dose escalation. Risk of medullary thyroid carcinoma (based on
rodent data, precautionary contraindication in personal/family history of MEN2 or MTC) is a
labeled warning. The drug interacts with oral medications by delaying gastric emptying —
hormonal contraceptives and drugs requiring rapid absorption may need separate timing.